103 related articles for article (PubMed ID: 12850528)
21. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma.
Vaishampayan UN; Heilbrun LK; Shields AF; Lawhorn-Crews J; Baranowski K; Smith D; Flaherty LE
Invest New Drugs; 2007 Feb; 25(1):69-75. PubMed ID: 16937078
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of thalidomide in renal-cell carcinoma.
Escudier B; Lassau N; Couanet D; Angevin E; Mesrati F; Leborgne S; Garofano A; Leboulaire C; Dupouy N; Laplanche A
Ann Oncol; 2002 Jul; 13(7):1029-35. PubMed ID: 12176780
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Atzpodien J; Kirchner H; Rebmann U; Soder M; Gertenbach U; Siebels M; Roigas J; Raschke R; Salm S; Schwindl B; Müller SC; Hauser S; Leiber C; Huland E; Heinzer H; Siemer S; Metzner B; Heynemann H; Fornara P; Reitz M
Br J Cancer; 2006 Aug; 95(4):463-9. PubMed ID: 16909131
[TBL] [Abstract][Full Text] [Related]
25. Low-dose thalidomide in patients with metastatic renal cell carcinoma.
Tunio MA; Hashmi A; Qayyum A; Naimatullah N; Masood R
J Pak Med Assoc; 2012 Sep; 62(9):876-9. PubMed ID: 23139966
[TBL] [Abstract][Full Text] [Related]
26. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
May M; Helke C; Bock M; Hoschke B
Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
[TBL] [Abstract][Full Text] [Related]
27. [Effect of second-line treatment with capecitabine and thalidomide in patients with advanced pancreatic cancer].
Shi SB; Ma TH; Tang XY; Li CH
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):301-4. PubMed ID: 23985261
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma.
Pagliaro LC; Perez CA; Tu SM; Daliani DD
Urol Oncol; 2006; 24(6):487-91. PubMed ID: 17138128
[TBL] [Abstract][Full Text] [Related]
29. Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma.
Nathan PD; Gore ME; Eisen TG
J Clin Oncol; 2002 Mar; 20(5):1429-30. PubMed ID: 11870194
[No Abstract] [Full Text] [Related]
30. Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma.
Ang SF; Tan SH; Toh HC; Poon DY; Ong SY; Foo KF; Choo SP
Am J Clin Oncol; 2012 Jun; 35(3):222-7. PubMed ID: 21378539
[TBL] [Abstract][Full Text] [Related]
31. The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer.
McCollum AD; Wu B; Clark JW; Kulke MH; Enzinger PC; Ryan DP; Earle CC; Michelini A; Fuchs CS
Am J Clin Oncol; 2006 Feb; 29(1):40-4. PubMed ID: 16462501
[TBL] [Abstract][Full Text] [Related]
32. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM; Pfister C; Berdah JF; Benhammouda A; Salze P; Monnier A; Paule B; Guillet P; Chretien Y; Brewer Y; Di Palma M; Untereiner M; Malaurie E; Tadrist Z; Pavlovitch JM; Hauteville D; Mejean A; Azagury M; Mayeur D; Lucas V; Krakowski I; Larregain-Fournier D; Abourachid H; Andrieu JM; Chastang C
J Clin Oncol; 1998 Jul; 16(7):2505-13. PubMed ID: 9667271
[TBL] [Abstract][Full Text] [Related]
33. A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
Stadler WM; Desai AA; Quinn DI; Bukowski R; Poiesz B; Kardinal CG; Lewis N; Makalinao A; Murray P; Torti FM
Cancer Chemother Pharmacol; 2008 Apr; 61(4):689-94. PubMed ID: 17569043
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of capecitabine combined with thalidomide in second-line treatment of advanced pancreatic cancer.
Shi SB; Wang M; Niu ZX; Tang XY; Liu QY
Pancreatology; 2012; 12(6):475-9. PubMed ID: 23217281
[TBL] [Abstract][Full Text] [Related]
35. The treatment of advanced renal cell cancer with high-dose oral thalidomide.
Stebbing J; Benson C; Eisen T; Pyle L; Smalley K; Bridle H; Mak I; Sapunar F; Ahern R; Gore ME
Br J Cancer; 2001 Sep; 85(7):953-8. PubMed ID: 11592764
[TBL] [Abstract][Full Text] [Related]
36. A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma.
Srinivas S; Guardino AE
BJU Int; 2005 Sep; 96(4):536-9. PubMed ID: 16104906
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial of thalidomide and interleukin-2 in patients with metastatic renal cell carcinoma.
Olencki T; Malhi S; Mekhail T; Dreicer R; Elson P; Wood L; Bukowski RM
Invest New Drugs; 2006 Jul; 24(4):321-6. PubMed ID: 16683075
[TBL] [Abstract][Full Text] [Related]
38. Cytotoxic chemotherapy for metastatic renal cell carcinoma.
Stadler WM
Urologe A; 2004 Sep; 43 Suppl 3():S145-6. PubMed ID: 15164180
[No Abstract] [Full Text] [Related]
39. Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer.
Burris HA; Jones SF; Shipley D; Meluch AA; Greco FA; Barton JH; Yardley DA; Hainsworth JD
Cancer Invest; 2010 May; 28(4):408-12. PubMed ID: 20210519
[TBL] [Abstract][Full Text] [Related]
40. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
